Ovarian Cancer Patients Benefit from Lynparza Maintenance Tablets, Trial Suggests

Ovarian Cancer Patients Benefit from Lynparza Maintenance Tablets, Trial Suggests
Ovarian cancer patients who have an inherited BRCA mutation, and who responded to platinum-based chemotherapy, benefit from using Lynparza (olaparib) tablets as a maintenance treatment, a clinical trial suggests. The Phase 3 SOLO-2 trial (NCT01874353) of the AstraZeneca therapy in tablet form met its primary goal of increasing patients' progression-free survival -- the length of time their disease fails to worsen. Patients on the tablets lived 13.6 months longer than those on a placebo, the trial investigators said. The U.S. Food and Drug Administration (FDA) has approved Lynparza capsules for use against cancer, but not the tablet form yet. Another measure of progression-free survival in the SOLO-2 trial, the Blinded Independent Central Review (BICR) scale, suggested an even larger 24.7-month improvement in the tablet takers' progression-free survival. The results were presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer March 13-15 in National Harbor, Maryland. “The SOLO-2 data demonstrated a statistically significant and clinically meaningful improvement in outcomes for those who took olaparib," Richard Penson, MD, associate professor of Medicine at Harvard Medical School, said in a news release. "The results, which showed a delay in disease progression in the maintenance setting, highlight the impact of PARP inhibition at the forefront of the important advances we are making in targeting ovarian cancer,"
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *